PATENT CLAIM ANALYSIS

Application Number: 15773653
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "186100"]

Abstract:
Respiratory syncytial virus (RSV) infection may lead to severe respiratory illness in young children. Thus, there is a need for a live attenuated vaccine, which would mimic the natural course of infection without causing illness; however, restricting viral replication also reduces the immune response. Reported herein is a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein that surprisingly induced a stronger immune response to RSV than previous vaccine candidates despite being more restricted in replication.

Claim (Index 12):
The method of  claim 1 , wherein the RSV genome or antigenome comprises the nucleotide sequence of SEQ ID NO: 1.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 93.0
- Lexical Diversity: 1.35821
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16061314', '10934003', '09887469', '10722000', '10754895']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7920967547500389
- 35 USC 102 Novelty (BERT): 0.5572529297723662
- Combined Prediction Score: 0.7686123722522716
- Mean Citation Score: 420.56412
- Max Citation Score: 433.09232
- Similarity Product: 342.5678715140724

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test